| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA788: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy |
|
Medicine details |
|
| Medicine name | avelumab (Bavencio®) |
| Formulation | intravenous infusion |
| Reference number | 3038 |
| Indication | Monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy |
| Company | Merck KGaA |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/01/2021 |
| NICE guidance | |
| Commercial arrangement | PAS |